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AbstrACt
Objective To assess the relationship between risk factor 
clusters and cardiovascular disease (CVD) incidence in 
Asian and Caucasian populations and to estimate the 
burden of CVD attributable to each cluster.
setting Asia Pacific Cohort Studies Collaboration.
Participants Individual participant data from 34 
population-based cohorts, involving 314 024 participants 
without a history of CVD at baseline.
Outcome measures Clusters were 11 possible 
combinations of four individual risk factors (current 
smoking, overweight, blood pressure (BP) and total 
cholesterol). Cox regression models were used to obtain 
adjusted HRs and 95% CIs for CVD associated with 
individual risk factors and risk factor clusters. Population-
attributable fractions (PAFs) were calculated.
results During a mean follow-up of 7 years, 6203 CVD 
events were recorded. The ranking of HRs and PAFs was 
similar for Australia and New Zealand (ANZ) and Asia; 
clusters including BP consistently showed the highest HRs 
and PAFs. The BP–smoking cluster had the highest HR for 
people with two risk factors: 4.13 (3.56 to 4.80) for Asia 
and 3.07 (2.23 to 4.23) for ANZ. Corresponding PAFs were 
24% and 11%, respectively. For individuals with three 
risk factors, the BP–smoking–cholesterol cluster had the 
highest HR (4.67 (3.92 to 5.57) for Asia and 3.49 (2.69 to 
4.53) for ANZ). Corresponding PAFs were 13% and 10%.
Conclusions Risk factor clusters act similarly on CVD risk 
in Asian and Caucasian populations. Clusters including 
elevated BP were associated with the highest excess risk 
of CVD.
IntrOduCtIOn
Cardiovascular disease (CVD) is the main 
contributor to morbidity and mortality 
worldwide and over 80% of CVD deaths 
take place in low-income and middle-in-
come countries.1 Much of the burden of 
CVD is modifiable by adequate control 
of a set of key risk factors: elevated blood 
pressure, cigarette smoking, elevated blood 
lipids, excess body weight and diabetes.2 3 
The Global Burden of Disease study showed 
that each of these individual cardiovascular 
risk factors were among the top 10 causes of 
loss of disability-adjusted life years.4 Large 
international case-control studies, INTER-
HEART2 and INTERSTROKE,3 have quanti-
fied the individual contribution of these risk 
factors to CVD and highlighted the substan-
tial geographic variation in the burden of 
CVD attributable to particular risk factors. 
For instance, abdominal obesity was a great 
contributor to CVD risk in Western Europe, 
North America and South-East Asia, while it 
was a smaller contributor in China.2 3 
Cardiovascular risk factors cluster within 
individuals and clustering of risk factors 
has been associated with a higher risk of 
CVD.5 6 Hence, information on the risks 
strengths and limitations of this study
 ► Strengths of this study are the large sample size, 
prospective design and the inclusion of studies 
among diverse populations across the Asia-Pacific 
region.
 ► We did not have sufficient cardiovascular disease 
(CVD) events to allow for the reliable quantification 
of associations between risk factor clusters and the 
risk of major subtypes of CVD, such as coronary 
heart disease   and stroke, or sex-specific effects 
within regions.
 ► Most cohorts included in the Asia Pacific Cohort 
Studies Collaboration were initiated around 20 years 
ago, before the epidemiological transition during the 
past few decades in Asia.
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associated with clusters is relevant for targeting preven-
tion, management and treatment strategies. This is 
particularly of relevance for Asia, as region where the 
burden of CVD is still rising, yet where data on the 
burden of risk factor clusters are limited.
The Asia Pacific Cohort Studies Collaboration 
(APCSC) has conducted a series of studies to eval-
uate the joint effects of two risk factors (combinations 
of excess body weight, elevated systolic blood pres-
sure (SBP), elevated total cholesterol, diabetes and ciga-
rette smoking) and to compare the effects in Asian and 
Caucasian populations.7–16 Although several national 
and international guidelines on cardiovascular risk 
factor management use sets of individual risk factors to 
estimate the absolute 10-year risk, direct comparisons of 
risk factor clusters have not been made nor have clus-
ters with more than two risk factors been analysed in 
APCSC. Therefore, the aim of the present study was to 
assess the relationship between multiple risk factor clus-
ters and the risk of CVD in Asian and Caucasian popula-
tions and to estimate the burden of CVD attributable to 
each of these clusters.
MethOds
The APCSC is an individual participant data overview 
comprising 44 cohort studies in the Asia Pacific region. 
Details of the APCSC, and characteristics of the included 
studies have been described previously.17 Studies from 
mainland China, Hong Kong, Japan, Korea, Singa-
pore, Taiwan or Thailand were classified as Asian, 
while studies from Australia and New Zealand (ANZ) 
were classified as Caucasian. For the present study, only 
those studies with information on smoking status, blood 
pressure, total cholesterol and body mass index (BMI) 
were included (34 studies). The prevalence of diabetes 
was relatively low in the included studies (6% in Asia, 
and 4% in ANZ), which can in part be explained by 
the inclusion of studies that conducted their base-
line surveys before the rapid rise in the prevalence of 
diabetes. For that reason, clusters with diabetes were 
not included. Participants with known coronary heart 
disease (CHD) and stroke at baseline were excluded. 
The primary study outcome was the incidence of fatal or 
non-fatal CVD (International Classification of Diseases 
Ninth Revision 410–414, 430–438).
Cardiovascular risk factors
Methods of measurement of baseline risk factors have 
been described previously.17 Smoking status was deter-
mined from self-report questionnaires. BMI was calcu-
lated from measured body weight (in kilograms) divided 
by measured height (in metres) squared. Overweight 
was defined as a BMI ≥25 kg/m2.18 Elevated blood pres-
sure was defined as SBP ≥140 mm Hg or diastolic blood 
pressure ≥90 mm Hg,19 and elevated cholesterol was 
defined as total cholesterol ≥5.2 mmol/L.20
statistical analyses
HRs and 95% CIs for different risk factor clusters were 
estimated from Cox proportional hazards regression 
models. The models were adjusted for age and strati-
fied by sex and study. To facilitate comparisons, we also 
assessed the corresponding associations for individual 
risk factors. The reference group consisted of individ-
uals without any of the four risk factors. The population 
attributable fractions (PAFs) for CVD due to risk factor 
clusters were calculated using the observed prevalence 
estimates and the HRs as described above. The formula 
was21:
 
prevalence∗(HR−1)
1+prevalence∗(HR−1) 
Risk factor clusters were mutually exclusive in calcu-
lating the HRs, but were not mutually exclusive in calcu-
lating the PAFs. Prevalences and PAFs were estimated 
separately by region, and, in secondary analyses, by sex. 
As a sensitivity analysis, individuals with a history of 
diabetes were excluded.
results
baseline characteristics
Overall, 314 024 individuals were included in the anal-
yses, of whom 74% were from Asia, and 59% were men 
(table 1 and online supplementary etable 1). Partici-
pants in Asia were 4 years younger (mean age, 47 years) 
than those in ANZ. Caucasian participants had higher 
levels of BMI, SBP and total cholesterol. Smoking was 
more common in Asian participants, which was due to 
high smoking rates in men.
risk factors and risk factor clusters and in relation to 
cardiovascular events
During a mean follow-up of 7 years, 6203 CVD events 
were recorded. The ranking of HRs by individual risk 
factors and risk factor clusters was similar in ANZ 
and Asia (figure 1 and table 2). The blood pressure–
smoking cluster had the highest HR in people with two 
risk factors (HR (95% CI): 4.13 (3.56 to 4.80) in Asia 
and 3.07 (2.23 to 4.23) in ANZ and the cholesterol–
overweight cluster had the lowest HR: 1.25 (0.94 to 
1.65) in Asia and 1.79 (1.39 to 2.29) in ANZ. For indi-
viduals with three risk factors, the blood pressure–
smoking–cholesterol cluster had the highest (HR 4.67 
(3.92 to 5.57) in Asia and 3.49 (2.69 to 4.53) in ANZ; 
the smoking–cholesterol–overweight cluster had the 
lowest HR (2.00 (1.51 to 2.67) in Asia and 3.30 (2.51 to 
4.35) in ANZ). HRs in individuals with four risk factors 
were 5.66 (4.61 to 6.95) in Asia and 4.35 (3.38 to 5.59) 
in ANZ. Rankings of HRs were broadly similar between 
sexes (figure 2 and table 2).
Prevalence and PAFs
The prevalence of individual risk factors and risk factor 
clusters and associated PAFs are shown in table 2, 
figure 3 and online supplementary etable 2. Clusters 
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including smoking had the highest PAFs in Asian men, 
with a PAF of 37% for the blood pressure–smoking 
cluster. The blood pressure–cholesterol cluster had 
the highest PAF in men in ANZ (30%), followed by 
the blood pressure–overweight (28%), and smoking–
cholesterol (20%) clusters. The blood pressure–choles-
terol and blood pressure–overweight clusters had the 
highest PAFs in women in both regions; the PAFs were 
17% and 13% in Asian women and 36% and 34% in 
women from ANZ. The prevalence of smoking in 
Asian women is very low, which explains the compar-
atively low PAFs for risk factor clusters involving 
smoking.
The main findings did change minimally after 
exclusion of individuals with a history of diabetes 
(online supplementary etables 3 and 4).
dIsCussIOn
This study of over 320 000 individuals in the Asia-Pa-
cific region found that the ranking of the relations 
between clusters of major modifiable risk factors for 
CVD and risk of cardiovascular events was similar in 
Asia and ANZ. In both regions, the greatest excess 
risks of CVD were found in clusters involving elevated 
blood pressure. However, differences in the prevalence 
of risk factors between sexes and regions led to varia-
tion in the burden of CVD attributable to risk factor 
clusters.
The present study is the first to examine the relation-
ships between clusters of two, three or four risk factors 
and cardiovascular events. We confirm that all combi-
nations of risk factors are related to an increased risk 
of CVD, and that the risk increases in the presence of 
additional risk factors. Through direct comparisons, 
we identified that the most hazardous clusters for CVD 
where those that included high blood pressure. Further-
more, we expanded the evidence by showing that clus-
ters act broadly similar on the risk of CVD in Asian and 
Caucasian populations.
High blood pressure, smoking, unfavourable lipid 
levels, high BMI and diabetes are each independently 
related to an increased risk of CVD, and the more risk 
factors are present in an individual, the higher these 
risks are. Previous reports from the APCSC on the 
joint effects of several combinations of two risk factors 
broadly showed that the risk of CVD increased at all 
combinations, with an indication for synergism for 
some CVD subtypes.7–16 For example, where high SBP 
is an important risk factor for CVD in people with and 
without diabetes and irrespective of levels of BMI,9 15 
it may be more strongly related to the risk of CVD at 
lower levels at TC.7 Similarly, smoking seemed to exac-
erbate the impact of high SBP on the risk of haemor-
rhagic stroke10 and that of BMI, TC and high-density 
lipoprotein cholesterol on the risk of CHD.11 12 Hence, 
effective strategies that target combinations of specific 
risk factors, such as smoking cessation and weight loss S
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or blood pressure reduction, could have a greater 
impact than anticipated on reducing the burden 
of CVD.
The major shift in causes of death and disability from 
infectious diseases to non-communicable diseases and 
increases in life expectancy seen over the past decades 
pose major challenges on the capacities of health 
systems globally. These challenges are most profound 
in low-income and middle-income countries where the 
burden of CVD is the largest, competing health threats 
are still present and resources are most limited.22 
Prevention of CVD through targeting its major modifi-
able risk factors is arguably the most cost-effective way 
to reduce the burden of CVD. From the public health 
perspective, our findings indicate that the largest 
burden of CVD is attributable to elevated blood pres-
sure and smoking, suggesting that interventions on 
curbing smoking habits and managing blood pressure 
levels could have major benefits in terms of reducing 
the burden of CVD worldwide. However, local contexts 
need to be considered. Taking smoking, for example, 
implementing effective smoking bans, raising taxes 
and the price of tobacco have been effective ways to 
reduce tobacco use in low-income and middle-income 
countries.23 In contrast, bans on advertising in the 
mass media to denormalise smoking and behavioural 
interventions at the individual level are current strat-
egies to reduce the smoking prevalence in high-in-
come countries, where bans on smoking in public 
places have largely been implemented. Reduction in 
dietary salt intake is another major strategy to avert 
the burden of elevated blood pressure; such strate-
gies need to be tailored to the national situation given 
substantial differences in dietary habits globally. The 
risk factor clusters with overweight did not rank as 
high as anticipated. The relatively low PAFs found in 
our study may be due to the lower prevalence of over-
weight some decades ago, when the measurements of 
BMI were done. Since then, the prevalence of over-
weight and obesity has dramatically increased globally. 
While further follow-up of existing cohorts and new 
cohorts are needed to monitor the obesity epidemic 
and the evolution of the relative risks, contemporary 
information on the burden of the risk factors and their 
clustering should become available to local authorities 
when trying to target their own needs and priorities. 
Yet, surveillance of the prevalence of risk factor clus-
ters is not available for many countries.
Strengths of this study include its large sample size, 
prospective design and the inclusion of studies among 
diverse populations across the Asia-Pacific region. 
Some limitations of this study need to be acknowl-
edged. First, despite the large sample size, we did not 
have sufficient CVD events to allow for reliable quanti-
fication of associations between risk factor clusters and 
the risk of major subtypes of CVD, such as CHD and 
stroke, or sex-specific effects within regions. However, 
CHD and stroke share many of the same risk factors, 
and preventive strategies to target clusters are likely 
to be beneficial in preventing both outcomes in both 
sexes and across regions. While the number of partic-
ipants from Asian cohorts was greater than from ANZ 
cohorts, the number of CVD events, and associated 
statistical power, was broadly similar between regions. 
Next, most cohorts from APCSC were initiated around 
20 years ago and one might question its suitability 
Figure 1 HRs and 95% CIs for incident cardiovascular disease associated with risk factors and risk factor clusters by region. 
Analyses are adjusted for age, and stratified by sex and study. Individuals without any elevated risk factor were the reference 
group. ANZ, Australia and New Zealand; P, high blood pressure; S, current smoking; C, high total cholesterol (TC), W, high body 
mass index (BMI). High blood pressure was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm 
Hg, high TC was defined as a TC level ≥5.2 mmol/L and high BMI was defined as a BMI≥25 kg/m2.
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to address current cardiovascular profiles, given the 
well-recognised epidemiological transition during the 
past few decades in Asia. However, the main purpose 
of this study was to evaluate the aetiological relation-
ships of clusters on risk of CVD, which are less likely 
to change over time. The historical nature of the data 
also precluded reliable analysis of clusters involving 
diabetes, which is a much commoner risk factor in 
current times. Data on prediabetes were also not avail-
able. Finally, ethnicity was not recorded in all studies. 
However, where we know it, less than 0.5% of partic-
ipants in Australia and New Zealand had an Asian 
ancestry. Hence, we feel that domicile is a reasonable 
proxy for ethnicity in our data.
Table 2 HRs (95% CIs), prevalence and population attributable fractions (PAFs) for incident cardiovascular disease 
associated with risk factors and risk factor clusters by sex and region
ANZ Asia
HR (95% CI) Prevalence PAF, % HR (95% CI) Prevalence PAF, %
Men
  P 1.79 (1.22 to 2.63) 42.5 25.1 2.44 (1.95 to 3.06) 27.8 28.6
  S 1.51 (1.01 to 2.27) 23.3 10.7 1.41 (1.16 to 1.71) 13.8 19.3
  C 1.33 (0.94 to 1.88) 60.3 16.5 1.19 (0.90 to 1.56) 61.5 6.5
  W 1.06 (0.71 to 1.58) 64.5 3.8 1.07 (0.73 to 1.58) 51.0 1.7
  PS 2.70 (1.83 to 4.00) 8.8 13.0 4.02 (3.32 to 4.86) 3.8 31.2
  PC 2.50 (1.81 to 3.46) 28.7 30.1 3.01 (2.36 to 3.84) 28.1 19.2
  PW 2.23 (1.60 to 3.11) 31.6 28.0 3.09 (2.37 to 4.03) 24.6 16.5
  SC 2.71 (1.94 to 3.79) 14.6 20.0 1.80 (1.45 to 2.24) 8.6 14.3
  SW 1.65 (1.03 to 2.64) 13.6 8.1 1.47 (1.06 to 2.02) 5.8 5.5
  CW 1.87 (1.37 to 2.57) 41.9 26.8 1.23 (0.83 to 1.83) 34.9 2.5
  PSC 3.16 (2.27 to 4.42) 6.1 11.7 4.38 (3.54 to 5.42) 3.0 17.4
  PSW 3.44 (2.31 to 5.11) 5.9 12.6 3.81 (2.97 to 4.90) 2.1 11.6
  PCW 2.51 (1.86 to 3.39) 21.8 24.7 3.25 (2.50 to 4.24) 18.7 9.6
  SCW 2.94 (2.09 to 4.13) 9.2 15.2 1.94 (1.42 to 2.65) 4.1 5.2
  PSCW 4.32 (3.16 to 5.92) 4.2 12.3 5.44 (4.29 to 6.90) 1.7 9.5
Women
  P 1.79 (1.07 to 2.97) 37.5 22.7 3.61 (2.90 to 4.49) 16.8 30.5
  S 1.60 (0.83 to 3.05) 13.8 7.6 1.42 (0.87 to 2.33) 3.0 1.3
  C 1.25 (0.83 to 1.87) 61.5 13.2 1.27 (0.98 to 1.63) 33.4 8.2
  W 1.15 (0.67 to 2.00) 51.0 7.3 1.39 (0.95 to 2.03) 17.8 6.5
  PS 4.95 (2.79 to 8.79) 3.8 13.1 4.78 (3.20 to 7.14) 0.9 3.1
  PC 2.22 (1.51 to 3.27) 28.1 25.5 3.57 (2.80 to 4.56) 7.8 16.7
  PW 2.16 (1.37 to 3.40) 24.6 22.2 3.51 (2.62 to 4.70) 6.0 13.1
  SC 1.47 (0.90 to 2.38) 8.6 3.9 2.79 (1.51 to 5.17) 1.0 1.8
  SW 2.15 (0.90 to 5.16) 5.8 6.3 2.49 (0.91 to 6.79) 0.7 1.0
  CW 1.47 (0.97 to 2.22) 34.9 14.0 1.20 (0.80 to 1.80) 8.3 1.6
  PSC 3.91 (2.56 to 5.96) 3.0 8.0 8.22 (4.79 to 14.10) 0.3 2.3
  PSW 2.80 (1.40 to 5.58) 2.1 3.7 8.49 (4.58 to 15.74) 0.3 1.9
  PCW 2.41 (1.65 to 3.53) 18.7 20.9 3.50 (2.65 to 4.63) 3.2 7.5
  SCW 3.95 (2.45 to 6.38) 4.1 10.8 1.62 (0.40 to 6.54) 0.3 0.2
  PSCW 3.83 (2.48 to 5.92) 1.7 4.6 5.00 (2.20 to 11.35) 0.1 0.5
HRs are adjusted for age and stratified by study. Individuals without any elevated risk factor were the reference group. 
Combinations of risk factors were not mutually exclusive in calculating the prevalence and population attributable fractions. 
ANZ, Australia and New Zealand; P, high blood pressure; S, current smoking; C, high total cholesterol (TC); W, high body 
mass index (BMI). High blood pressure was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure 
≥90 mm Hg, high TC was defined as a TC level ≥5.2 mmol/L and high BMI was defined as a BMI ≥25 kg/m2.
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In conclusion, clusters of major modifiable risk factors 
act similarly on the risk of CVD in Asian and Cauca-
sian populations. Risk factor clusters including elevated 
blood pressure were associated with the highest excess 
risk of CVD.
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Figure 2 HRs and 95% CIs for incident cardiovascular disease associated with risk factors and risk factor clusters by sex. 
Conversions as in figure 1.
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